Dr. Wainberg on the Rationale for the Phase 3 NAPOLI 3 Trial in Patients With PDAC
Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.
Dr. Wainberg on Liposomal Irinotecan/NALIRIFOX vs Nab-paclitaxel/Gemcitabine in PDAC
Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.
Dr. Wainberg on Optimal Frontline Treatment Strategies for Metastatic ESCC
Zev A. Wainberg, MD, discusses standard frontline treatment approaches for patients with metastatic esophageal squamous cell carcinoma and highlights data supporting the use of tislelizumab in combination with chemotherapy in ESCC.
Dr. Wainberg on the Need for Continued Enrollment to Clinical Trials in CRC
Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.
KRAS G12C Inhibitors in mCRC
A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.
Future Directions in mCRC
Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.
EGFR Therapy for mCRC: Dermatologic Toxicity
Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.
Later-Line Treatment Options for mCRC
Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.
Sequencing Anti-EGFR Therapy in mCRC
The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.
Changes in Cetuximab Dosing Schedule in mCRC
Reactions to recent changes approved by the FDA to the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.
Selecting Systemic Therapy for Newly Diagnosed mCRC
Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.
Next-Generation Sequencing in Metastatic Colorectal Cancer
Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.
Molecular Testing in Metastatic Colorectal Cancer
The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.
Trends in Colorectal Cancer Incidence
Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.
Dr. Wainberg on Optimal Dosing With Regorafenib in CRC
Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.
Dr. Wainberg on the Potential Role of Neoadjuvant Chemotherapy in Pancreatic Cancer
Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.
Dr. Wainberg on the Need for Chemotherapy-Free Options in CRC
Zev A. Wainberg, MD, discusses the need to develop chemotherapy-free options in colorectal cancer.
Dr. Wainberg on the FIGHT Trial Results in FGFR2b+ Gastric/GEJ Cancer
Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.
Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX
Dr. Wainberg on Impact of PD-L1 Status in Gastric/GEJ Cancer Treatment
Zev A. Wainberg, MD discusses the efficacy findings of pembrolizumab monotherapy versus chemotherapy for patients with PD-L1–positive advanced gastric and gastroesophageal junction cancer of high combined positive score in cohort 1 of the phase II KEYNOTE-059 and in the phase III KEYNOTE-061 and KEYNOTE-062 studies.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512